Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Phase 1 Unknown 18 enrolled Fudan University

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), so it can inhibit tumor angiogenesis. This phase I study aims to determine the drug's toxicity and to find a dose level to be used in a phase II study in solid tumor patients.

Timeline

Start: 2007-07
Primary completion: 2008-06
Completion: 2008-06

Publications

Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, Yv K, Wang F, Li C, Qian J, Zheng C, Zuo Y. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010 Oct 5;10:529. doi: 10.1186/1471-2407-10-529.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivoceranib	Small molecule	50 mg	Oral
Subject	Rivoceranib	Small molecule	100 mg	Oral
Subject	Rivoceranib	Small molecule	250 mg	Oral

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Summary

Timeline

Publications

Drugs

Indications